ev3 Inc. develops, manufactures, and commercializes technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. It offers plaque excision systems, stents, carotid stents, percutaneous transluminal angioplasty balloons, embolic protection devices, thrombus management systems, blood clot therapy products, procedural support products, embolization coils, liquid embolics, micro catheters, thrombectomy catheters, occlusion balloons, guidewires, and retrieval devices. The company sells its products through a network of distributors in the Asia Pacific, Latin America, Eastern Europe, and the Middle East. ev3 Inc. was formerly known as Microvena Corporation. The company was founded in 2000 and is headquartered in Plymouth, Minnesota with additional offices in Irvine, California; and Paris, France. It also has sales offices in Paris, France; Maastricht, the Netherlands; Canada; Beijing and Shanghai, China; Bonn, Germany; Milano, Italy; Upplands Väsby, Sweden; Adam Marszalek, Poland; Madrid, Spain; and Hertfordshire, United Kingdom. As of July 9, 2010, ev3 Inc. operates as a subsidiary of Covidien Group S.a.r.l.
